FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Tag Archives: FiercePharma
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Pfizer’s Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status – FiercePharma
FiercePharma |
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
FiercePharma Pfizer's first campaign for its new eczema drug Eucrisa kicks off with an appealing, kid-friendly "nose to toes" TV ad, but behind the lighthearted wordplay is the potential to capitalize on its first-to-market status. Pfizer's Eucrisa is an early … |
Sanofi’s eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat – FiercePharma
FiercePharma |
Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
FiercePharma But so far, the numbers on Sanofi's new eczema med look even better, according to Bill Sibold, EVP at Sanofi Genzyme. “Prescriptions are trending ahead of other recent biologic launches in dermatology, including Cosentyx,” Sibold said during the … Sanofi raises outlook but key eczema drug disappoints investors France's Sanofi Raises Earnings Forecast, Pleased With Eczema Drug Uptake Sanofi raises outlook but key eczema drug disappoints investors |